• 1
    Strum SB, Scholz MC, McDermed JE. The androgen deprivation syndrome: the incidence and severity in prostate cancer patients receiving hormone blockade. Proc Am Soc Clin Oncol 1998; 17: 316a
  • 2
    Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004; 10: 757582
  • 3
    Berruti A, Tucci M, Terrone C et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging 2002; 19: 899910
  • 4
    Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 254650
  • 5
    Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 227582
  • 6
    Sato N, Gleave ME, Bruchovsky N et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 13946
  • 7
    Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005; 23: 82128
  • 8
    Calais Da Silva F, Bono A. Phase III study of intermittent MAB versus continuous MAB. International co-operative study (abstract). In Whelan P, Brausi M, Queimadelos M, Portilho J, Kirkali Z eds. J Urol 2005; 173 (Suppl.): 309
  • 9
    De Leval J, Boca P, Yousef E et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1: 16371
  • 10
    Albrecht W, Collette L, Fava C et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44: 50511
  • 11
    Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 5304
  • 12
    De La Taille A, Zerbib M, Conquy S et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003; 91: 1822
  • 13
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 83945
  • 14
    Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51: 13744
  • 15
    Lane TM, Ansell W, Farrugia D et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 11722
  • 16
    Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 23340
  • 17
    Spry NA, Kristjanson L, Hooton B et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 108392
  • 18
    Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000; 5: 4552
  • 19
    Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 2003; 26: e11923
  • 20
    Mouraviev V, Gleave ME. A meaningful legacy: urologists as Nobel Prize laureates. Can J Urol 2003; 10: 173742
  • 21
    Akaza H, Homma Y, Usami M et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006; 98: 5739
  • 22
    Gulley JL, Figg WD, Steinberg SM et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy J Urol 2005; 173: 156771
  • 23
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 217984
  • 24
    Carroll PR. Early stage prostate cancer – do we have a problem with over-detection, overtreatment or both? J Urol 2005; 173: 10612